Cereno Scientific Reports Positive Safety and Tolerability Outcomes after One Year of CS1 Treatment in PAH from Expanded Access Program
GOTHENBURG, Sweden, March 31, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), a pioneering biotech firm focused on developing innovative treatments aimed at enhancing and prolonging life for…